The Cystic Fibrosis Foundation hosted a Congressional briefing on February 11 to discuss the benefits of the Foundation's model of specialized, coordinated care and its innovative strategies for drug development, and how they can serve as an example for other rare, chronic diseases.
The cystic fibrosis care model is evolving to support people living longer with CF and their increasingly diverse health needs. Catalyzed by the approval of Trikafta® and the COVID-19 pandemic, this adaptive and personalized care model encompasses novel ways to connect clinicians and patients.
Beginning this March, the CF Foundation's Patient Assistance Resource Center (PARC) will help implement a new tool for the Foundation's network of 110 cystic fibrosis care centers across the U.S. to help make it easier for care center staff to work with insurers to cover CF treatment and care.
A decade of strategic efforts to improve care has played a profound role in improving the quality and length of life for people with cystic fibrosis in the United States, according to a series of reports published in the April issue of BMJ Quality & Safety (formerly the British Medical Journal).
The Cystic Fibrosis Foundation has arranged for over 10,000 home spirometers to be provided to care centers to support continued access to high quality, comprehensive care during the COVID-19 pandemic.
Nine cystic fibrosis care centers were awarded the 2013 - 2014 Cystic Fibrosis Quality Care Award for outstanding service to people with CF and their families at the 28th annual North American Cystic Fibrosis Conference in Atlanta.